Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells.

Reinhardt A, Liu H, Ma Y, Zhou Y, Zang C, Habbel JP, Possinger K, Eucker J.

Anticancer Res. 2018 May;38(5):2669-2682.

PMID:
29715087
2.

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.

Marmé F, Gomez-Roca C, Graudenz K, Huang F, Lettieri J, Peña C, Trnkova ZJ, Eucker J.

Cancer Chemother Pharmacol. 2018 Apr;81(4):727-737. doi: 10.1007/s00280-018-3540-9. Epub 2018 Feb 21.

PMID:
29468456
3.

Delayed release of chemokine CCL25 with bioresorbable microparticles for mobilization of human mesenchymal stem cells.

Fröhlich K, Hartzke D, Schmidt F, Eucker J, Gurlo A, Sittinger M, Ringe J.

Acta Biomater. 2018 Mar 15;69:290-300. doi: 10.1016/j.actbio.2018.01.036. Epub 2018 Feb 2.

PMID:
29408710
4.

Influence of Chemotherapy on the Antioxidant Status of Human Skin.

Lee BN, Jung S, Darvin ME, Eucker J, Kühnhardt D, Sehouli J, Chekerov R, Patzelt A, Fuss H, Yu RX, Lademann J.

Anticancer Res. 2016 Aug;36(8):4089-93.

PMID:
27466518
5.

Cisplatin Plus Ifosfamide with/without Etoposide as Salvage Treatment in Heavily-pre-treated Patients with Metastatic Breast Cancer.

Habbel P, Kurreck A, Schulz CO, Regierer AC, Kaul D, Scholz CW, Neumann C, Possinger K, Eucker J.

Anticancer Res. 2015 Sep;35(9):5091-5.

PMID:
26254412
6.

Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer.

Zang C, Eucker J, Habbel P, Neumann C, Schulz CO, Bangemann N, Kissner L, Riess H, Liu H.

Cell Cycle. 2015;14(8):1291-9. doi: 10.4161/15384101.2014.995050.

7.

The multi-tyrosine kinase inhibitor TKI258, alone or in combination with RAD001, is effective for treatment of human leukemia with BCR-ABL translocation in vitro.

Eucker J, Zang C, Zhou Y, Li X, Habbel P, Neumann C, Scholz C, Liu H.

Anticancer Res. 2014 Sep;34(9):4909-14.

PMID:
25202073
8.

TKI258, a multi-tyrosine kinase inhibitor is efficacious against human infant/childhood lymphoblastic leukemia in vitro.

Eucker J, Zang C, Zhou Y, Li X, Habbel P, Schulz CO, Scholz C, Liu H.

Anticancer Res. 2014 Sep;34(9):4899-907.

PMID:
25202072
9.

Severe Case of Autoimmune Thrombocytopenia First Diagnosed in Pregnancy.

Bolten K, Salama A, Thomas A, Eucker J, Henrich W.

Geburtshilfe Frauenheilkd. 2013 Dec;73(12):1252-1255.

10.

An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients.

Regierer AC, Wolters R, Ufen MP, Weigel A, Novopashenny I, Köhne CH, Samonigg H, Eucker J, Possinger K, Wischnewsky MB.

Ann Oncol. 2014 Mar;25(3):633-8. doi: 10.1093/annonc/mdt539. Epub 2013 Dec 23.

11.

Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.

Meyer AH, Stroux A, Lerch K, Eucker J, Eitle J, Hohloch K, Andrzejak M, Possinger K, Dörken B, Pezzutto A, Scholz CW.

Ann Oncol. 2014 Jan;25(1):210-5. doi: 10.1093/annonc/mdt507.

PMID:
24356632
12.
13.

Reverse differentiation as a gene filtering tool in genome expression profiling of adipogenesis for fat marker gene selection and their analysis.

Ullah M, Stich S, Häupl T, Eucker J, Sittinger M, Ringe J.

PLoS One. 2013 Jul 26;8(7):e69754. doi: 10.1371/journal.pone.0069754. Print 2013.

14.

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions.

Müller BM, Keil E, Lehmann A, Winzer KJ, Richter-Ehrenstein C, Prinzler J, Bangemann N, Reles A, Stadie S, Schoenegg W, Eucker J, Schmidt M, Lippek F, Jöhrens K, Pahl S, Sinn BV, Budczies J, Dietel M, Denkert C.

PLoS One. 2013 Jun 27;8(6):e68252. doi: 10.1371/journal.pone.0068252. Print 2013.

15.

Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.

Zang C, Eucker J, Liu H, Coordes A, Lenarz M, Possinger K, Scholz CW.

Leuk Lymphoma. 2014 Feb;55(2):425-34. doi: 10.3109/10428194.2013.806800. Epub 2013 Jul 25.

PMID:
23721513
16.

Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.

Karle J, Bolbrinker J, Vogl S, Kreutz R, Denkert C, Eucker J, Wischnewsky M, Possinger K, Regierer AC.

Breast Cancer Res Treat. 2013 Jun;139(2):553-60. doi: 10.1007/s10549-013-2565-3. Epub 2013 May 18.

PMID:
23686417
17.
18.

Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas.

Korfel A, Elter T, Thiel E, Hänel M, Möhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz C, Metzner B, Röth A, Birkmann J, Schlegel U, Martus P, Illerhaus G, Fischer L.

Haematologica. 2013 Mar;98(3):364-70. doi: 10.3324/haematol.2012.077917. Epub 2012 Dec 14.

19.

Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.

Zang C, Eucker J, Liu H, Müller A, Possinger K, Scholz CW.

Cancer Lett. 2013 Oct 10;339(2):288-97. doi: 10.1016/j.canlet.2012.11.013. Epub 2012 Nov 27.

PMID:
23200668
20.

The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer--a phase I trial.

Schwarzlose-Schwarck S, Scholz CW, Regierer AC, Martus P, Neumann C, Habbel P, Liu H, Zang C, Schefe JH, Schulz CO, Possinger K, Eucker J.

Anticancer Res. 2012 Aug;32(8):3435-41.

PMID:
22843927
21.

Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.

Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.

Anticancer Res. 2012 May;32(5):1627-37.

PMID:
22593441
22.

Breast Cancer-Associated Thrombotic Microangiopathy.

Regierer AC, Kuehnhardt D, Schulz CO, Flath B, Jehn CF, Scholz CW, Possinger K, Eucker J.

Breast Care (Basel). 2011 Dec;6(6):441-445. Epub 2011 Dec 15.

23.

5FU continuous infusion in heavily pretreated advanced breast cancer patients.

Regierer AC, Reinecke F, Weigel A, Dieing A, Lehenbauer-Dehm S, Schwarzlose-Schwarck S, Possinger K, Eucker J.

Onkologie. 2011;34(12):696-700. doi: 10.1159/000334550. Epub 2011 Nov 21.

PMID:
22156449
24.

Primary tumor excision in stage IV breast cancer at diagnosis without influence on survival: a retrospective analysis and review of the literature.

Rosche M, Regierer AC, Schwarzlose-Schwarck S, Weigel A, Bangemann N, Schefe JH, Scholz CW, Possinger K, Eucker J.

Onkologie. 2011;34(11):607-12. doi: 10.1159/000334061. Epub 2011 Oct 28. Review.

PMID:
22104157
25.

The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.

Liu H, Zang C, Schefe JH, Schwarzlose-Schwarck S, Regierer AC, Elstner E, Schulz CO, Scholz C, Possinger K, Eucker J.

Anticancer Res. 2011 Sep;31(9):2713-22.

PMID:
21868512
26.

[Individualized treatment of breast cancer].

Eucker J, Possinger K.

Dtsch Med Wochenschr. 2011 Mar;136(10):486-91. doi: 10.1055/s-0031-1274532. Epub 2011 Mar 1. Review. German.

PMID:
21365526
27.

Diagnostic and therapeutic use of membrane proteins in cancer cells.

Grimm D, Bauer J, Pietsch J, Infanger M, Eucker J, Eilles C, Schoenberger J.

Curr Med Chem. 2011;18(2):176-90. Review.

PMID:
21110808
28.

Solid neuroendocrine carcinomas of the breast: metastases or primary tumors?

Richter-Ehrenstein C, Arndt J, Buckendahl AC, Eucker J, Weichert W, Kasajima A, Schneider A, Noske A.

Breast Cancer Res Treat. 2010 Nov;124(2):413-7. doi: 10.1007/s10549-010-1178-3. Epub 2010 Sep 25.

PMID:
20872069
29.

Induction of endoplasmic reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor alpha/gamma, in human breast cancer cells.

Zang C, Liu H, Bertz J, Possinger K, Koeffler HP, Elstner E, Eucker J.

Mol Cancer Ther. 2009 Aug;8(8):2296-307. doi: 10.1158/1535-7163.MCT-09-0347. Epub 2009 Aug 11.

30.

Therapeutic implication of BAL in patients with neutropenia.

Kuehnhardt D, Hannemann M, Schmidt B, Heider U, Possinger K, Eucker J.

Ann Hematol. 2009 Dec;88(12):1249-56. doi: 10.1007/s00277-009-0747-1. Epub 2009 May 5.

PMID:
19415277
31.

Primary peripheral primitive neuroectodermal tumor/Ewing's tumor of the testis in a 46-year-old man-differential diagnosis and review of the literature.

Heikaus S, Schaefer KL, Eucker J, Hogrebe E, Danebrock R, Wai DH, Krenn V, Gabbert HE, Poremba C.

Hum Pathol. 2009 Jun;40(6):893-7. doi: 10.1016/j.humpath.2008.11.009. Epub 2009 Mar 9. Review.

PMID:
19269015
32.

Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.

Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K, Eucker J.

Eur J Pharmacol. 2008 Sep 4;591(1-3):43-51. doi: 10.1016/j.ejphar.2008.06.026. Epub 2008 Jun 12.

PMID:
18588872
33.

Contrast-Enhancing Meningeal Lesions Are Associated with Longer Survival in Breast Cancer-Related Leptomeningeal Metastasis.

Regierer AC, Stroux A, Kühnhardt D, Dieing A, Lehenbauer-Dehm S, Flath B, Possinger K, Eucker J.

Breast Care (Basel). 2008;3(2):118-123. Epub 2008 Apr 15.

34.

Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia.

Burmeister T, Schwartz S, Taubald A, Jost E, Lipp T, Schneller F, Diedrich H, Thomssen H, Mey UJ, Eucker J, Rieder H, Gökbuget N, Hoelzer D, Thiel E.

Haematologica. 2007 Dec;92(12):1699-702.

35.

[Systemic therapy of male breast cancer].

Eucker J, Kühnl A, Possinger K.

Zentralbl Chir. 2007 Oct;132(5):396-9. German.

PMID:
17907081
36.

Dual PPARalpha/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines.

Zang C, Liu H, Waechter M, Eucker J, Bertz J, Possinger K, Koeffler HP, Elstner E.

Cell Cycle. 2006 Oct;5(19):2237-43. Epub 2006 Oct 1.

PMID:
17102607
37.

[Treatment of breast cancer: from hormones to antibodies].

Eucker J, Emde A, Possinger K.

Internist (Berl). 2006 Dec;47(12):1223-4, 1226-8. Review. German.

PMID:
17063333
38.

Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma.

Eucker J, Sterz J, Krebbel H, Zavrski I, Kaiser M, Zang C, Heider U, Jakob C, Elstner E, Sezer O.

Anticancer Drugs. 2006 Aug;17(7):763-9.

PMID:
16926626
39.

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.

Heider U, Kaiser M, Sterz J, Zavrski I, Jakob C, Fleissner C, Eucker J, Possinger K, Sezer O.

Eur J Haematol. 2006 Jan;76(1):42-50.

PMID:
16343270
40.

[Berlin Society of Internal Medicine].

Eucker J, Possinger K.

Med Klin (Munich). 2004 Nov 15;99(11):684. German. No abstract available.

PMID:
15583880
41.

Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma.

Eucker J, Bängeroth K, Zavrski I, Krebbel H, Zang C, Heider U, Jakob C, Elstner E, Possinger K, Sezer O.

Anticancer Drugs. 2004 Nov;15(10):955-60.

PMID:
15514564
42.

Rapid and simple differentiation of C. dubliniensis from C. albicans.

Graf B, Trost A, Eucker J, Göbel UB, Adam T.

Diagn Microbiol Infect Dis. 2004 Feb;48(2):149-51.

PMID:
14972386
43.

Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection.

Heider U, Fleissner C, Zavrski I, Jakob C, Dietzel T, Eucker J, Ockenga J, Possinger K, Sezer O.

Eur J Haematol. 2004 Jan;72(1):64-6.

PMID:
14962266
44.

Identification of clinically relevant yeasts by PCR/RFLP.

Trost A, Graf B, Eucker J, Sezer O, Possinger K, Göbel UB, Adam T.

J Microbiol Methods. 2004 Feb;56(2):201-11.

PMID:
14744449
45.

Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion.

Eucker J, Eikel D, Heider U, Jakob C, Zavrski I, Gatz F, Mergenthaler HG, Jungclas H, Possinger K, Sezer O.

Anticancer Drugs. 2003 Nov;14(10):793-9.

PMID:
14597873
46.
47.

Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion.

Zavrski I, Naujokat C, Niemöller K, Jakob C, Heider U, Langelotz C, Fleissner C, Eucker J, Possinger K, Sezer O.

J Cancer Res Clin Oncol. 2003 Jul;129(7):383-91. Epub 2003 Jul 8.

PMID:
12851815
48.

Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III.

Niemöller K, Jakob C, Heider U, Zavrski I, Eucker J, Kaufmann O, Possinger K, Sezer O.

J Cancer Res Clin Oncol. 2003 Apr;129(4):234-8. Epub 2003 Apr 17.

PMID:
12700896
49.

Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.

Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J, Possinger K, Hofbauer LC, Sezer O.

Clin Cancer Res. 2003 Apr;9(4):1436-40.

50.

The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas.

Eucker J, Schille C, Schmid P, Jakob C, Schetelig J, Kingreen D, Mergenthaler HG, Huhn D, Possinger K, Sezer O.

Anticancer Drugs. 2002 Oct;13(9):907-13.

PMID:
12394253

Supplemental Content

Loading ...
Support Center